Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

A key operational challenge in radiopharmaceutical development is the need for a reliable supply of radionuclides for fresh, just-in-time labeling before dosing. This contrasts sharply with conventional drugs that can be manufactured in bulk and stored, adding significant logistical complexity.

Companies are moving away from single, hyper-efficient global supply chains. The new strategy involves setting up parallel, regional manufacturing locations (e.g., China plus the US, or China plus Mexico and Vietnam) to create redundancy and mitigate risks from disruptions like pandemics, natural disasters, or geopolitical events.

Novartis's radioligand drugs have a radioactive half-life requiring delivery from factory to patient within 4-5 days. Building and mastering a global supply chain to handle this extreme logistical complexity at 99.9% on-time delivery creates a significant competitive advantage that is difficult for others to replicate.

When facing threats like ground stations becoming military targets, the most effective resilience strategy isn't hardening individual sites. Instead, it's proliferation: making systems cheap, modular, and fast to deploy in large numbers. This ensures that the loss of any single asset is not catastrophic to the network.

While tariffs affected sourcing, the COVID-19 pandemic was the main catalyst for pharma reshoring. The crisis exposed critical vulnerabilities in global supply chains for essential precursors and chemicals, creating a stronger impetus for companies to establish local manufacturing than trade policy alone.

For final drug product manufacturing, Actuate engaged two separate US-based partners. This parallel track strategy provided crucial redundancy during the COVID pandemic, ensuring that a shutdown or material shortage (e.g., glass vials) at one plant wouldn't derail their clinical programs.

Defense tech startup Terra is building separate manufacturing hubs across Africa instead of a central one. This strategy is driven by the continent's diverse security challenges. Different regions require different hardware—like desert drones for West Africa versus maritime USVs for East Africa—making localized production and expertise essential.

Scaling complex cell therapies follows a similar trajectory to monoclonal antibodies. The strategy involves establishing a global footprint with regional manufacturing facilities (e.g., US West, US East, Europe) to serve distinct geographic areas. This approach ensures manageable logistics and reliable delivery for personalized medicines, leveraging historical lessons.